Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?

American journal of clinical oncology - 1 Feb 2013

Kim Seung Tae, Jung Hae-Yun, Sung Jae Sook, Jo Uk Hyun, Tanaka Tomoaki, Hagiwara Koichi, Park Kyong Hwa, Shin Sang Won, Kim Jun Suk, Kim Yeul Hong

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations as prognostic or predictive marker in patients with non-small cell lung cancer (NSCLC) have been used widely. However, it may be difficult to get tumor tissue for analyzing the status of EGFR mutation status in large proportion of patients with advanced disease. PATIENTS AND METHODS: We obtained pairs of tumor and serum samples from 57 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to DNA Mutational Analysis

Share to Genes, erbB-1

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 22237146
DOI: 10.1097/COC.0b013e31823a5217

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?PMID 22237146Read ↗

Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?Semantic proximity Read ↗

Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Plasma EGFR Mutation Detection Associated With Survival Outcomes in Advanced-Stage Lung Cancer.Semantic proximity Read ↗

Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis.Semantic proximity Read ↗

Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer.Semantic proximity Read ↗

Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients.Semantic proximity Read ↗

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.Semantic proximity Read ↗

A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.Semantic proximity Read ↗

Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Associations between epidermal growth factor receptor gene mutation and serum tumor markers in advanced lung adenocarcinomas: a retrospective study.Semantic proximity Read ↗

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.